Granza Bio

Granza Bio is an early-stage biotech leveraging a foundational discovery from the University of Oxford to develop a new class of immunotherapies. Its core technology platform is built around 'attack particles,' which are natural, cell-free weapons of the immune system that can be engineered for precise targeting. The company is in the pre-clinical research phase, working to translate this discovery into programmable therapeutics for oncology and inflammatory conditions. As a private, pre-revenue entity, its near-term focus is on validating its platform and advancing its first programs toward the clinic.

Platform for engineering 'attack particles'—autonomous, cell-free cytotoxic entities released by immune cells—to reprogram them for target-specific killing of diseased cells.

Granza Bio competes in the targeted therapy space against CAR-T/NK cell therapies, bispecific antibodies, and antibody-drug conjugates. Its differentiation lies in its cell-free approach, which may offer manufacturing and safety advantages if successfully developed.